NCT06981858View on ClinicalTrials.gov

A Single-Arm Exploratory Study of Enlansibumab Sequentially Combined With Concurrent Chemoradiotherapy for Locally Advanced Cervical Cancer

PHASE2Not yet recruitingINTERVENTIONAL

Enrollment

34

Participants

Timeline

Start Date

May 15, 2025

Primary Completion Date

February 1, 2029

Study Completion Date

February 1, 2029

Conditions

LOCALLY ADVANCED CERVICAL CANCERS

Interventions

DRUG

Enlonstobart Injection

Sequential Enlonstobart Injection with concurrent chemoradiotherapy

All Listed Sponsors

lead

Chongqing University Cancer Hospital

OTHER